FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond

The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidaemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) represent a major economic burden on healthcare systems. Patients with at-risk MASH,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of hepatology 2024-09, Vol.81 (3), p.562-576
Hauptverfasser:	Harrison, Stephen A., Rolph, Tim, Knott, Madeline, Dubourg, Julie
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Fatty Liver - drug therapy Fatty Liver - etiology Fatty Liver - metabolism FGF21 analogs Fibroblast Growth Factors - metabolism Humans liver fibrosis MASH MASLD Metabolic Diseases - drug therapy Metabolic Diseases - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!